Gene
SMO
SMO is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (15), Actionable biomarkers (3), Trial mentions (22), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SMO. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 9 of 11,460 | 0.08% |
| 2022 | 0 of 8,285 | 0.00% | 11 of 13,598 | 0.08% |
| 2021 | 0 of 8,692 | 0.00% | 11 of 15,045 | 0.07% |
| 2020 | 1 of 7,640 | 0.01% | 6 of 14,459 | 0.04% |
| 2019 | 2 of 7,300 | 0.03% | 11 of 12,159 | 0.09% |
| 2018 | 1 of 6,927 | 0.01% | 9 of 11,854 | 0.08% |
| 2017 | 2 of 6,558 | 0.03% | 5 of 11,595 | 0.04% |
Showing 10 of 37 years.
Assay-provider ledger (15)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Agilent Technologies | Reagent supplier | Clinical validation | 1 | June 01, 2018 |
| Illumina | Unclassified | Clinical validation | 2 | June 01, 2018 |
| Promega | Reagent supplier | Clinical validation | 1 | June 01, 2018 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 1 | June 01, 2018 |
| AB Applied Biosystems | Reagent supplier | Analytical validation | 1 | November 17, 2015 |
Showing 5 of 15 assay-provider companies.
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W) | Vismodegib | responsive | basal cell carcinoma | Cancer Genome Interpreter |
| SMO (P641A) | Vismodegib | response-associated | lung carcinoma | Cancer Genome Interpreter |
| SMO (D473H) | Vismodegib | responsive | medulloblastoma | Cancer Genome Interpreter |
Trial mentions (22)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06357988 | Trial eligibility (AACT) |
| NCT02091141 | Trial eligibility (AACT) |
| NCT03052478 | Trial eligibility (AACT) |
| NCT03390296 | Trial eligibility (AACT) |
| NCT03767439 | Trial eligibility (AACT) |
Showing 5 of 22 trial mentions.
Target-disease associations (407)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ACTH-Producing Pituitary Gland Adenoma | cancer or benign tumor | Cancer Gene Census |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Angiomatous Meningioma | cancer or benign tumor | Cancer Gene Census |
| Arrhythmogenic right ventricular dysplasia | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 407 associations.
Vendor sourcing (62)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.000025, PM2_M). In silico tool predictions suggest... | View ClinVar record SCV002058343.1 |
| Alliance for Clinical Trials in Oncology | Trial sponsor | Mentioned in trial textTrial free-text mention | SMO | View trial NCT02523014 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein ... | View ClinVar record SCV003540327.2 |
| Anne Chang | Trial sponsor | Mentioned in trial textTrial free-text mention | SMO | View trial NCT01529450 |
| Astellas Pharma (Japan) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * Patients who underwent parathyroid intervention within 24 weeks prior to the informed consent * Patients who have primary hyperparathyroidism * Having a... | View trial NCT01872026 |
Showing 5 of 62 sourcing records.
Trial-cited literature (113)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023 | 58 |
| ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial. | BMC cancer | 2023 | 28 |
| Prenatal diagnosis by trio exome sequencing in fetuses with ultrasound anomalies: A powerful diagnostic tool. | Frontiers in genetics | 2023 | 23 |
| Characterising paediatric mortality during and after acute illness in Sub-Saharan Africa and South Asia: a secondary analysis of the CHAIN cohort using a machine learning approach. | EClinicalMedicine | 2023 | 17 |
| Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine. | Haematologica | 2023 | 15 |
Showing 5 of 113 papers.
Protein variant mentions (16)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A001M | 1 | 2022 | PMID 34462336 |
| p.A459V | 1 | 2022 | PMID 36455049 |
| p.D473N | 2 | 2016 to 2023 | PMID 36814246, PMID 26546616 |
| p.D477G | 1 | 2019 | PMID 31480477 |
| p.F252L | 1 | 2015 | PMID 25741868 |
Showing 5 of 16 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.R763* | CCDI-MCI | Cystic, Mucinous and Serous Neoplasms; Granular Cell Tumors and Alveolar Soft Part Sarcomas; Specialized Gonadal Neoplasms; Neoplasms, NOS; Adenomas and Adenocarcinomas; Gliomas; Meningiomas; Acinar Cell Neoplasms; Odontogenic Tumors; Soft Tissue Tumors and Sarcomas, NOS; Nevi and Melanomas; Malignant Lymphomas, NOS or Diffuse; Epithelial Neoplasms, NOS; Thymic Epithelial Neoplasms; Other and unspecified parts of mouth; Rectosigmoid junction; Thyroid gland; Connective, subcutaneous and other soft tissues; Peripheral nerves and autonomic nervous system; Other endocrine glands and related structures; Retroperitoneum and peritoneum; Vagina; Other and ill-defined digestive organs; Pancreas; Renal pelvis; Bladder; Nasal cavity and middle ear; Meninges; Adrenal gland; Bones, joints and articular cartilage of limbs; Bones, joints and articular cartilage of other and unspecified sites; Breast; Skin; Thymus; Esophagus; Other and ill-defined sites in lip, oral cavity and pharynx; Larynx; Other and unspecified urinary organs; Brain; Testis; Heart, mediastinum, and pleura; Rectum; Nasopharynx; Palate; Prostate gland; Base of tongue; Accessory sinuses; Other and unspecified female genital organs; Lip; Spinal cord, cranial nerves, and other parts of central nervous system; Colon; Oropharynx; Other and ill-defined sites; Unknown; Other and ill-defined sites within respiratory system and intrathoracic organs; Other and unspecified male genital organs; Cervix uteri; Bronchus and lung; Eye and adnexa; Ovary; Small intestine; Lymph nodes; Stomach | 1 | 3,033 | 0.03% | 0.01% to 0.19% |
| p.S533N | TCGA-READ | Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Colon; Unknown; Rectum; Rectosigmoid junction; Connective, subcutaneous and other soft tissues | 1 | 171 | 0.58% | 0.10% to 3.24% |
Literature-extracted relations (6)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Itraconazole | Chemical | negative_correlate |
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. | 2010 |
| Neoplasms | Disease | associate |
Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial. | 2022 |
| Craniosynostoses | Disease | associate |
Clinical genetics of craniosynostosis. | 2017 |
| Basal Cell Carcinoma | Disease | associate |
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. | 2016 |
| Pancreatic Neoplasms | Disease | associate |
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer. | 2015 |
Showing 5 of 6 relation assertions.
Organizations publishing (176)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| University of Michigan | Academic | 8 | 2011 to 2022 |
| Government of the United States of America | Government | 7 | 2010 to 2022 |
| The University of Texas System | Academic | 7 | 2015 to 2022 |
| Duke University Health System | Academic | 5 | 2015 to 2021 |
| Mayo Clinic | Hospital | 5 | 2012 to 2020 |
Showing 5 of 176 organizations.
Where SMO appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- respiratory or thoracic disease
352 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.